Contributor Page
Arnold & Porter
By Paul Pompeo, Amanda J. Sherwood
What happens when the existence of a bid protest impacts contract administration? The Armed Services Board of Contract Appeals (ASBCA or the Board) recently addressed such a scenario in Advanced...
By Amy Jeffress
Arnold & Porter White Collar Defense partner Amy Jeffress was featured on a recent segment of BBC Radio 4's The Briefing Room discussing
By John Barker, John Bellinger, III, Charles Blanchard, Ronald Lee, Nancy L. Perkins, Nicholas Townsend, Tom McSorley
The proposed rules are open for public comment through October 24, 2019.
By Lawrence E. Culleen, Michael D. Daneker, Sean Morris, Allison B. Rumsey, Thomas Santoro
This quarterly newsletter provides updates on litigation, regulatory, legislative, and other notable developments involving chemicals of concern to business.
By Bryant M. Godfrey
For almost a century, the United States government has criminalized the production, distribution, and sale of cannabis.
By Ethan Shenkman
President Trump withdrew the Obama guidance by executive order in March 2017.
By Alan Rothman
Are there too many lawsuits in this country?
By John Barker, John Bellinger, III, Charles Blanchard, Ronald Lee, Nancy L. Perkins, Nicholas Townsend, Tom McSorley
Below we describe key elements of the proposed rules on which interested parties may wish to submit comments.
By Ethan Shenkman
That natural gas will be burned in those power plants.
By Samuel Goodman, Danielle N. Craft
The CJEU will leave it to the EU member states' national regulators to assess these measures.
By Scott Feira, John P. Elwood, Peter J. Schildkraut
Opponents of the 2018 Order had a similarly expansive reading of the court's rejection of the attempt at preemption.
By Alan Rothman
Welcome to the latest installment of And Now a Word from the Panel, a column which "rides the circuit" with the Judicial Panel on Multidistrict Litigation as it meets on a bimonthly basis at venues around the country.
By Colette R. Deamer
Viridis's use of the BOSWELAN mark during the clinical trial was purely internal in nature.
By Murad Hussain, Kirk Ogrosky, Nora Schneider
The trial was bifurcated into two evidentiary phases: falsity and knowledge.
By Kirk Ogrosky, Michael A. Rogoff, Murad Hussain, Emily Reeder
This case may be over, but DOJ's interest in private equity firms that operate in areas with significant FCA exposure is not.
Contributor's Topics